https://doi.org/10.4081/aiua.2025.14332
Sexual safety and efficacy of a pollen extract and teupolioside-based supplement in men with benign prostatic hyperplasia: a prospective observational study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 30 September 2025
Background: Benign prostatic hyperplasia (BPH) is a common age-related condition that often results in lower urinary tract symptoms (LUTS), reduced quality of life, and sexual dysfunction. Conventional pharmacotherapies, while effective, are frequently associated with adverse effects on sexual and ejaculatory function. This study evaluated the sexual safety and clinical efficacy of a dietary supplement containing pollen extract and teupolioside, in men with BPH.
Methods: In this prospective, single-arm observational study, 25 men with moderate LUTS due to BPH received daily pollen extract and teupolioside supplementation for 90 days. The primary endpoints were sexual function (International Index of Erectile Function, IIEF-5), ejaculatory function (Male Sexual Health Questionnaire–Ejaculatory Dysfunction, MSHQ-EjD), quality of life (IPSS-QoL), and patient global impression of improvement (PGI-I). Secondary endpoints included changes in urinary flow (Qmax) and LUTS severity (International Prostate Symptom Score, IPSS). Assessments were conducted at baseline, 1 month, and 3 months.
Results: Sexual and ejaculatory functions remained stable over the treatment period, with no statistically significant deterioration observed. QoL improved significantly by the 3-month mark (IPSS-QoL median score reduced from 3 to 2; p<0.008), and PGI-I scores reflected high patient satisfaction (median 2, IQR 1). Qmax significantly increased from 12.4 mL/s at baseline to 15.5 mL/s at 3 months (p<0.001), and IPSS scores significantly declined from 11 to 8 (p<0.008), indicating improved urinary function.
Conclusions: The pollen extract and teupolioside supplementation was well tolerated and associated with improved QoL and urinary outcomes, without compromising sexual or ejaculatory function. These findings support its potential as a non-pharmacologic adjunct in the management of BPH, particularly in patients concerned about sexual side effects. Further randomized controlled studies are warranted to confirm these results.
Downloads
1. Cornu, JN, Gacci M, Hashim H, et al. EAU guidelines on non neurogenic male lower urinary tract symptoms (LUTS). European Association of Urology. Last updated April 23, 2025.
2. Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112:432-41. DOI: https://doi.org/10.1111/bju.12118
3. Fusco F, Creta M, De Nunzio C, et al. Progressive bladder remodelingdue to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans. BMC Urol. 2018;18:15. DOI: https://doi.org/10.1186/s12894-018-0329-4
4. Serati M, Andersson KE, Dmochowski R, et al. Systematic review of combination drug therapy for non-neurogenic lower urinary tract symptoms. Eur Urol. 2019; 75:129-168. DOI: https://doi.org/10.1016/j.eururo.2018.09.029
5. Korkina LG, Mikhal’chik EV, Suprun MV, et al. Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. Cell Mol Biol (Noisy-le-grand) 2007; 53:84-91.
6. Locatelli M, Macchione N, Ferrante C, et al. Graminex pollen: phenolic pattern, colorimetric analysis and protective effects in immortalized prostate cells (PC3) and rat prostate challenged with LPS. Molecules. 2018; 23:1145. DOI: https://doi.org/10.3390/molecules23051145
7. Lo Re M, Pezzoli M, Cadenar A, et al. Discovering a new nutraceutical based on pollen extract and teupolioside: a prospectivemonocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients. Arch Ital Urol Androl. 2025;97:13412. DOI: https://doi.org/10.4081/aiua.2025.13412
8. Muraca L, Scuteri A, Burdino E, et al. Effectiveness and safety of a new nutrient fixed combination containing pollen extract plus teupolioside, in the management of LUTS in patients with benign prostatic hypertrophy: a pilot study. Life (Basel) 2022;12:965. DOI: https://doi.org/10.3390/life12070965
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.